Simon obtained his Ph.D. in Molecular Biology from Université de Montréal in 2015, where he used high-throughput screening to identify novel embryonic stem cell fate determinants. He then did his post-doctoral studies at EPFL, in Switzerland, using CRISPR/Cas9 to establish new in vitro models of polycystic kidney diseases. In 2019, he returns to the Sauvageau Team as a research associate to develop genetic screening strategies to characterize compounds targeting various AML subtypes.

Research Associate